Low-grade nasopharyngeal papillary adenocarcinoma: a case report and review of the literature

This article was published in the following Dove Press journal:
OncoTargets and Therapy
18 May 2016
Number of times this article has been viewed

Abstract: Low-grade nasopharyngeal papillary adenocarcinoma is an extremely rare tumor, with only a limited number of cases reported in the literature. Some published studies have paid more attention to the clinicopathological features of nasopharyngeal adenocarcinoma, while little effort has been made to study the optimal therapeutic strategies. We report about a woman diagnosed with low-grade nasopharyngeal papillary adenocarcinoma. She received the treatment approach that combined transnasal endoscopic surgery to remove the lesion with postoperative radiotherapy for nasal cavity. There was no evidence of recurrence after 4 months of surgery, and further follow-up is being continued. Through this example, we wanted to explore the optimal therapeutic strategies for primary nasopharyngeal adenocarcinomas.

Keywords: nasopharyngeal adenocarcinoma, immunohistochemistry, treatment policy, survival and prognosis

Introduction

Nasopharyngeal carcinoma (NPC) is commonly diagnosed in Southeastern Asia, particularly in southern China.1 It originates from the epithelial lining of the nasopharynx and has a variety of pathological subtypes. The vast majority of NPC cases are keratinizing or nonkeratinizing squamous cell carcinoma.2 Additional pathological types of NPC, which include adenocarcinoma, lymphoma, sarcoma, and minor salivary gland tumor, constitute <5% of all NPC cases.3,6 Therefore, primary nasopharyngeal adenocarcinomas (NPACs) are extremely rare, with only a limited number of cases reported in the literature.1,2 Having obtained written informed consent from the patient and approval of the research ethics board of Shandong Cancer hospital, we report a case of primary low-grade nasopharyngeal papillary adenocarcinoma (LGNPPA) in a 36-year-old woman who was treated in our hospital. We also include a review of the literature in order to highlight what we know to date about this rare entity.

Case report

A 36-year-old Chinese woman presented with a 2-year history of bilateral nasal obstruction and mild postnasal drip. It did not vary in severity during this period. No bloody sputum, epistaxis, tinnitus, otitis media, facial pain, aural fullness, or any other complaint was mentioned. A computed tomography (CT) scan of the head and neck showed bilateral mucosal thickening in the maxillary sinus, a soft tissue density in the ethmoid and sphenoid sinuses, and a soft tissue mass in the nasopharynx (Figure 1). There was no additional relevant medical history. The cervical lymph nodes were not

Xiaoli Wang 1,2
Hongjiang Yan 1
Yijun Luo 1,2
Tingyong Fan 1
1 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, 2 School of Medicine and Life Sciences, Shandong Academy of Medical Sciences, University of Jinan, Jinan, People's Republic of China

Correspondence: Tingyong Fan
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jyan Road 440, Jinan 250117, Shandong Province, People's Republic of China
Tel/fax +86 531 6762 6921
Email fanty681105@163.com
Wang et al
departmental nature of the lesion and the benign appearance, transnasal endoscopic resection was undertaken. In the surgical treatment, a papillary pedicle mass of size 0.7 cm, which was pedunculated and freely mobile, was found on the roof of the nasopharynx. Subsequently, the mass was resected with its stalk. The tumor was completely excised on endoscopy with an adequate surgical margin. Hematoxylin and eosin staining was performed for microscopic examination, and the lesion was characterized by papillary and glandular epithelial proliferation (Figure 2). Postoperative histopathology showed a low-grade papillary adenocarcinoma, and surgical margin was negative. According to the patient’s strong will after surgery and the cases reported in the literature, she had accepted postoperative radiotherapy (PORT) for nasal cavity with a total dose of 60 gray in 30 fractions over 6 weeks in our hospital. There was no evidence of recurrence after 4 months of surgery, and further follow-up is being carried out.

Discussion
The most common malignancy in the nasopharynx is NPC. By and large, the most common nasopharyngeal neoplasm is nonkeratinizing and keratinizing squamous cell carcinomas without glandular differentiation. Primary NPACs as a group are extremely rare tumors, which are reported to occupy 0.48% of all types of NPC.

Primary NPACs can be classified into two main categories: the conventional or mucosal surface origin type...
and the salivary gland type, with different morphological features and clinical behavior.\textsuperscript{2,3,7–10} Nasopharyngeal papillary adenocarcinoma, which belongs to the former category, has been reported in the literature.\textsuperscript{7} A retrospective study first described LGNPPAs as a distinct entity in a series of nine patients in 1988.\textsuperscript{7} There have been several case reports or small series in the literature about this entity after this seminal paper.\textsuperscript{7,9–12} Primary salivary gland-type nasopharyngeal carcinoma belongs to the latter category, which involves two main pathological subtypes: adenoid cystic carcinoma and mucoepidermoid carcinoma.\textsuperscript{2,9,13}

The case we presented was LGNPPA, which according to the World Health Organization is defined LGNPPA as phylloides papillary and glandular structures with exophytic growth characteristics of low-grade adenocarcinoma.\textsuperscript{8} Papillary NPAC is a special type of low-grade malignant carcinoma, and its morphology is similar to papillary thyroid carcinoma, which requires identification with the metastasis of papillary thyroid carcinoma. Thyroid transcription factor-1 (TTF-1) is generally deemed to be specific to the thyroid gland and the lung. However, some reports have occasionally shown positive immunohistochemical reactivity for TTF-1 in nasopharyngeal papillary adenocarcinoma.\textsuperscript{8,10} Therefore, TTF-1 protein might not be a suitable marker for distinguishing between primary or metastatic nasopharyngeal papillary adenocarcinoma. But the negative reactivity for thyroglobulin and CK20 promotes distinguishing metastatic thyroid papillary carcinoma from LGNPPA.\textsuperscript{10} Our case was diagnosed as LGNPPA because both derived from the epithelial surface and had a negative thyroid scan.

Recent and past studies are consistent in revealing the presence of Epstein–Barr virus (EBV) to be closely linked with the development and carcinogenesis of type II and III tumors.\textsuperscript{2,4} EBV DNA as a molecular marker is universally associated with the nonkeratinizing subtype of NPC.\textsuperscript{14} Some studies have detected low-expression levels of EBV markers in the NPAC tissue.\textsuperscript{2,15} Therefore, the relationship between NPACs and EBV is still uncertain. Further examination is still needed because of the extreme rarity of this tumor.

The treatment policy of primary NPACs is mainly chosen according to the clinical stage and histological grade of the tumor.\textsuperscript{6,16} Owing to the rarity of these cancers, the management of the lesions is usually empirically based, and no standard treatment exists for the tumors. Controversy exists as to whether radiotherapy alone, surgical treatment alone, or surgery combined with radiotherapy is the optimal therapeutic approach.

Several studies recommended that surgery combined with radiotherapy may be the main treatment policy for limited and resectable NPACs, such as adenoid cystic carcinoma, mucoepidermoid carcinoma, and well-differentiated adenocarcinoma.\textsuperscript{6,17} A retrospective study by Liu et al\textsuperscript{16} revealed that the overall survival in T1–T2 patients was significantly improved comparing combined surgical treatment group (n=12) with the nonsurgical (radiotherapy) treatment group (n=12; \( P=0.041 \)). Multivariate analysis also indicated that surgical treatment was an independent predictor of survival in such patients (\( P=0.017 \)), which is consistent with the results of Guo et al\textsuperscript{2} and Liu et al.\textsuperscript{15} However, some studies revealed that the addition of PORT could not bring survival benefit for early-stage (stages I and II) patients with clear margin and without adverse prognostic factors such as lymphovascular or perineural invasion, which is a set of conditions usually restricted to low-grade variants.\textsuperscript{7,19,20} On the basis of the patient’s strong will and the cases reported in the literature, she had accepted PORT. Therefore, large multicentric studies or studies with large sample size should be conducted to further evaluate whether PORT is necessary or not for early stage lesions.

For the poorly differentiated or unresectable primary NPACs, regardless of the conventional and salivary gland type, it is very difficult to achieve the purpose of radical cure with surgery alone. Indications for definitive radiotherapy included early-stage tumors with positive surgical margin, poorly differentiated carcinoma, perineural invasion, and deep muscle invasion. Also, high-grade (poorly differentiated) adenocarcinomas are relatively radiosensitive, and radiotherapy or chemoradiotherapy is currently considered as the primary treatment policy for such patients.\textsuperscript{17} Chemotherapy was also administered to patients, but no obvious benefit of treatment was found in some studies.\textsuperscript{16,21} No matter how rare this tumor is, further studies are still needed to ensure the efficacy of chemotherapy.

Our case presented as a T1N0M0 lesion was low-grade papillary NPAC, and the lesion was resected completely. Surgical resection is the mainstay of treatment for limited or resectable lesions, and complete resection can achieve excellent prognosis. In some studies, follow-up data have not reported local recurrence or metastatic disease ranging from 5 years to 20 years after complete surgical removal.\textsuperscript{3,7,9,10} In a study by Wenig et al,\textsuperscript{3} one patient failed primary radiotherapy treatment and subsequently underwent surgical resection as a salvage and had been free of disease over an 11-year period.\textsuperscript{7} The disease-free survival has no difference compared with those receiving surgery alone. It indicated the predominance
of surgery in the treatment of LGNPPA. Therefore, although our case had only a 4-month of follow-up, we can still predict its excellent prognosis.

However, owing to anatomical limitations and poor exposure of the tumor in the nasopharynx, it is sometimes difficult to completely remove the tumor with an adequate safety margin, especially in cases of large infiltrative tumors. Therefore, adjuvant treatment was needed to manage such tumors, which cannot be removed completely. Unfortunately, low-grade papillary NPACs, which belong to the type of well-differentiated adenocarcinomas, have low sensitivity to conventional radiotherapy or chemoradiotherapy, and it became a problem to deal with incompletely removed tumors.

Several studies revealed that photodynamic therapy (PDT) is a new treatment modality for head and neck cancers, with satisfactory treatment responses and minimal complications. In a study by Wang et al, PDT combined with topical 5-aminolevulinic acid as an effective modality of the postoperative adjuvant therapy was successfully used in the patient to eradicate the residual disease, without compromising the quality of life of the patient. Primary papillary NPAC is able to become qualified candidate for PDT, due to the limited lesions and low incidence of lymph node metastasis. PDT may be a more suitable alternative method to be the adjuvant therapy for incompletely resectable tumors.

Controversy also exists regarding the prognosis about the two categories of primary NPACs. Pineda-Daboin et al reported that the common-type NPAC is usually maintained as a low-grade malignancy and is associated with a good prognosis, while the prognosis of salivary gland-type NPACs is weak overall. However, a study by Guo et al showed that patients with common-type or salivary gland-type NPAC had no significant differences in survival rates (63% versus 69%, respectively). A study by Liu et al showed that all patients with the conventional NPAC or salivary gland-type NPAC had no significant differences in survival rates (63% versus 69%, respectively). A study by Liu et al showed that all patients with the conventional NPAC or salivary gland-type NPAC had no significant differences in survival rates (63% versus 69%, respectively).

References